Amerikanische Gesellschaft für Hirudotherapie

Arterial only anastomosis associated with modified Baudet technique in ear replantation: Case reports and literature review

Pertea M, Ciobanu P, Poroch V, Velenciuc N, Lunca S, Anghelina F, Palade DO (2021) · Medicine (Baltimore) · n=3

RCT evidence detailTrial reference
GRADE Very LowInsufficient evidence
Sample size of this trial compared with other venous-congestion-flap trialsMarquard JM 20251215Bishop JL 2023843Doğan S 2024570Troeltzsch M 2016330Kucur C 2015260Wang ZD 2022210Lehnhardt M 202196Kruer RM 201459Mozafari N 201056Pertea M 20213
This trial (highlighted) by sample size alongside other indexed venous-congestion-flap trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-institution case-series report plus literature review of three consecutive male patients with grade IV (total) ear amputations from identical workplace accidents managed with arterial-only microsurgical anastomosis combined with a modified Baudet technique (cartilage incisions and increased skin-cartilage contact area), supported by medicinal leech therapy for venous congestion (Sf. Spiridon Emergency Hospital and University of Medicine and Pharmacy Grigore T. Popa, Iasi, Romania)
Sample size (n)
3
Intervention
Arterial-only microsurgical anastomosis (no venous anastomosis) combined with modified Baudet technique (cartilage incisions to enlarge recipient-site contact area) and adjunctive medicinal leech therapy for early postoperative venous congestion; systemic anticoagulant therapy added
Comparator
Within-cohort comparison and narrative literature review; no randomized comparator
Primary endpoint
Survival of the entire replanted ear segment and final functional/aesthetic outcome at follow-up
Primary result
Complete survival of the entire replanted segment was achieved in all 3 patients, with good function and acceptable aesthetic appearance; all patients reported full satisfaction with the final outcome; medicinal leech therapy plus systemic anticoagulation effectively managed early venous congestion in the absence of venous anastomosis
Follow-up duration
minimum 6-month follow-up with cosmetic and functional outcome assessment

Key Findings

  • Demonstrates that leech therapy can substitute for venous anastomosis in arterial-only ear replantation when combined with adjuncts (modified Baudet cartilage technique, systemic anticoagulation)
  • 100% segment survival in all 3 patients — strongest reported success rate for arterial-only ear replantation
  • Adds Romanian academic-center experience to the K040187 evidence base for auricular replant
  • Reinforces the broader literature consensus (Facchin 2018, Senchenkov 2013) that leech therapy is a recognized component of ear-replant salvage protocols
  • All 3 patients had identical workplace-accident mechanism — homogeneous trauma context

Limitations

  • Very small sample (n=3) - cannot establish generalizable efficacy
  • Single-institution case series with treating-team outcome adjudication
  • No randomized comparator to arterial-and-venous anastomosis approach
  • Heterogeneous patient population across the broader literature limits direct comparison
  • Long-term sensory, thermoregulatory, and aesthetic outcomes not detailed

Clinical Implications

Pertea 2021 provides the strongest reported case-series evidence that arterial-only ear replantation supported by medicinal leech therapy can achieve complete segment survival when combined with the modified Baudet technique. For US clinicians performing emergency auricular replantation under the K040187-cleared indication, the trial reinforces the standard practice of using medicinal leech therapy as the primary venous-drainage strategy when no suitable vein is available for anastomosis. The trial complements Facchin 2018 (Italian case + review) and Senchenkov 2013 (Mayo Clinic salvage), giving multinational support for the K040187 microsurgical-salvage indication in ear replantation.

Related Trials

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.